← Back to Search

CDK4/6 Inhibitor

Ulixertinib + Palbociclib for Pancreatic Cancer

Phase 1
Recruiting
Led By Autumn McRee, MD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented disease refractory to at least one PD1/PD-L1 inhibitor
Metastatic pancreatic cancer or malignant melanoma patients who have received at least one line of therapy in the metastatic setting
Must not have
Unable or unwilling to discontinue use of certain drugs known to interact with study medications
Major surgery within 28 days prior to day -6 of ulixertinib
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to two years after treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Who is the study for?
Adults with advanced solid tumors, including pancreatic cancer or melanoma that's resistant to standard treatments. Participants must have an ECOG Performance Status of ≤2, a life expectancy ≥12 weeks, and adequate organ function. Women who can bear children need a negative pregnancy test and agree to use contraception.
What is being tested?
The trial is testing the combination of ulixertinib (an ERK inhibitor) with palbociclib (a CDK4/6 inhibitor) to find the safest dose with tolerable side effects for patients with specific types of advanced cancers.
What are the potential side effects?
Potential side effects are not specified in this summary but generally could include fatigue, nausea, diarrhea, blood count changes, and other drug-specific reactions based on their action on enzymes and cell cycle inhibition.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My condition did not improve after treatment with a PD1/PD-L1 inhibitor.
Select...
I have pancreatic cancer or melanoma and have been treated for it after it spread.
Select...
My melanoma cannot be removed by surgery and is in stage III or IV with certain genetic changes.
Select...
I have been treated with ipilimumab before.
Select...
My heart is strong, with a good pumping ability and normal heart rhythm.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
My advanced cancer does not respond to standard treatments.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot or will not stop taking drugs that could affect the study medication.
Select...
I have not had major surgery within the last 34 days.
Select...
I have a digestive issue that affects how my body absorbs medicine.
Select...
I have an autoimmune disease and take steroids for it.
Select...
I have or am at risk for eye conditions like RVO or CSR.
Select...
I have another cancer that is growing and needs treatment.
Select...
My cancer has spread to my brain under certain conditions.
Select...
I cannot swallow pills.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through treatment completion, approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through treatment completion, approximately 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum Tolerated Dose (MTD)
Secondary study objectives
Cancer Antigen 19-9 (CA19-9) response
Objective Response Rate
Overall Survival
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open-label, single arm Phase IExperimental Treatment2 Interventions
Ulixertinib added to palbociclib
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ulixertinib
2020
Completed Phase 1
~20
Palbociclib
2017
Completed Phase 3
~3790

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
365 Previous Clinical Trials
92,676 Total Patients Enrolled
4 Trials studying Melanoma
80 Patients Enrolled for Melanoma
BioMed Valley Discoveries, IncIndustry Sponsor
17 Previous Clinical Trials
564 Total Patients Enrolled
1 Trials studying Melanoma
13 Patients Enrolled for Melanoma
PfizerIndustry Sponsor
4,675 Previous Clinical Trials
28,717,184 Total Patients Enrolled
54 Trials studying Melanoma
49,508 Patients Enrolled for Melanoma
Autumn McRee, MDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
8 Previous Clinical Trials
333 Total Patients Enrolled
Hanna K Sanoff, MDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill

Media Library

Palbociclib (CDK4/6 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03454035 — Phase 1
Melanoma Research Study Groups: Open-label, single arm Phase I
Melanoma Clinical Trial 2023: Palbociclib Highlights & Side Effects. Trial Name: NCT03454035 — Phase 1
Palbociclib (CDK4/6 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03454035 — Phase 1
~3 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top